MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
4.570
+0.520
+12.84%
After Hours: 4.570 0 0.00% 19:59 05/20 EDT
OPEN
4.100
PREV CLOSE
4.050
HIGH
4.610
LOW
4.050
VOLUME
8.51M
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.940
MARKET CAP
1.40B
P/E (TTM)
-9.5288
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 18h ago
AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy
PUBT · 1d ago
AbCellera Insider Makes Bold Move With Fresh Share Purchase
TipRanks · 2d ago
Is AbCellera (ABCL) Quietly Rewriting Its Business Model With ABCL635’s Phase II Menopause Bet?
Simply Wall St · 2d ago
AbCellera director John S. Montalbano acquires 20,000 common shares for $95,400
PUBT · 2d ago
Weekly Report: what happened at ABCL last week (0511-0515)?
Weekly Report · 2d ago
A Look At AbCellera Biologics (ABCL) Valuation As ABCL-635 Advances Into Phase II Trials
Simply Wall St · 4d ago
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
Simply Wall St · 6d ago
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.